Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

NCT02440464 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

NIH

Sponsor class

Conditions

Multiple Myeloma

Interventions

PROCEDURE: Allogeneic HSCT
DRUG: Fludarabine
DRUG: Melphalan
DRUG: Bortezomib
DRUG: Ixazomib
DRUG: Placebo

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborators

[object Object]
[object Object]
[object Object]